<p>Apellis Pharmaceuticals, Inc.（納斯達克代碼：APLS - 獲取免費報告）首席會計官 James George Chopas 於 1 月 13 日（星期二）出售了 873 股該股票。股票的平均售價為 22.19 美元，總價值為 19,371.87 美元。出售完成後，首席會計官直接持有公司 52,595 股股票，價值約為 1,167,083.05 美元。這代表其持股比例減少了 1.63%。此次出售在向 SEC 的備案中披露，相關信息可通過 SEC 網站訪問。</p>
<h2>Apellis Pharmaceuticals 股票上漲 1.0%</h2>
<ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
<p>在週四的午盤交易中，納斯達克 APLS 的股票上漲了 0.20 美元，達到了 20.53 美元。該公司的交易量為 2,191,474 股，而其平均交易量為 3,495,767 股。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。公司的市值為 26 億美元，市盈率為 66.23，貝塔值為 0.31。該股票的 50 日移動平均線為 22.86 美元，200 日移動平均線為 23.41 美元。Apellis Pharmaceuticals, Inc.的 12 個月低點為 16.10 美元，12 個月高點為 31.17 美元。</p>
<p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）最近於 10 月 30 日（星期四）發佈了季度財報。公司報告該季度每股收益為 1.67 美元，超出市場共識預期的 1.03 美元，超出幅度為 0.64 美元。該季度的收入為 4.5858 億美元，而分析師預期為 3.6458 億美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。與去年同期相比，該季度的收入增長了 133.0%。在去年同期，該公司每股收益為（0.46）美元。整體來看，股票研究分析師預計 Apellis Pharmaceuticals, Inc.在當前年度將發佈-1.7 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>一些機構投資者最近調整了對 APLS 的持股。Parallel Advisors LLC 在第二季度將其在 Apellis Pharmaceuticals 的持股增加了 80.0%。Parallel Advisors LLC 目前持有該公司 1,924 股股票，價值 33,000 美元，此前在上個季度增持了 855 股。Jones Financial Companies Lllp 在第三季度將其在 Apellis Pharmaceuticals 的持股增加了 206.8%。Jones Financial Companies Lllp 目前持有該公司 2,037 股股票，價值 46,000 美元，此前在上個季度增持了 1,373 股。Allworth Financial LP 在第三季度將其在 Apellis Pharmaceuticals 的持股增加了 64.1%。Allworth Financial LP 目前持有該公司 2,194 股股票，價值 50,000 美元，此前在上個季度增持了 857 股。Osaic Holdings Inc.在第二季度將其在 Apellis Pharmaceuticals 的持股增加了 141.2%。Osaic Holdings Inc.目前持有該公司 2,682 股股票，價值 47,000 美元，此前在上個季度增持了 1,570 股。最後，Quantbot Technologies LP 在第三季度收購了 Apellis Pharmaceuticals 的新股份，價值 64,000 美元。機構投資者持有該公司 96.29% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位研究分析師對 APLS 股票發表了看法。花旗集團在 10 月 31 日（星期五）的研究報告中將 Apellis Pharmaceuticals 的目標價格從 52.00 美元下調至 45.00 美元，並對該股票給予 “買入” 評級。富國銀行在 10 月 15 日（星期三）的研究報告中開始覆蓋 Apellis Pharmaceuticals 的股票。他們給予 “增持” 評級，並設定 32.00 美元的價格目標。Needham &amp; Company LLC 在週二將 Apellis Pharmaceuticals 的目標價格從 29.00 美元下調至 28.00 美元，並對該公司給予 “買入” 評級。瑞穗證券在 11 月 3 日（星期一）的研究報告中將 Apellis Pharmaceuticals 的目標價格從 24.00 美元下調至 19.00 美元，並對該股票給予 “中性” 評級。最後，TD Cowen 在 10 月 31 日（星期五）的研究報告中將 Apellis Pharmaceuticals 的價格目標從 50.00 美元下調至 45.00 美元，並對該公司給予 “買入” 評級。共有 11 位研究分析師對該股票給予 “買入” 評級，7 位給予 “持有” 評級，2 位給予 “賣出” 評級。根據 MarketBeat，Apellis Pharmaceuticals 目前的共識評級為 “持有”，平均目標價格為 33.65 美元。</p>
<p><strong>閲讀我們最新的 APLS 股票分析</strong></p>
<h2>Apellis Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Apellis Pharmaceuticals, Inc.，以納斯達克代碼 APLS 交易，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。公司的研發工作集中在調節補體蛋白，以應對一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
<p>該公司的主要市場產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，並正在對其他視網膜疾病進行持續研究。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Apellis Pharmaceuticals</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 悄然激活</li>
<li>執行命令 14330：特朗普最大的舉措</li>
<li>崩盤已經開始（大多數人尚未察覺）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
<p>在考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Apellis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

APLS

<p>Apellis Pharmaceuticals 的首席會計官 James George Chopas 出售了 873 股，價格為每股 22.19 美元，總計 19,371.87 美元，減少了 1.63% 的持股，現持有 52,595 股，估值約為 117 萬美元。該交易已向美國證券交易委員會（SEC）披露。該股票最近的交易價格為 20.53 美元，市值為 26 億美元，市盈率為 66.23。分析師們的目標價格各不相同，花旗集團將其目標價從 52 美元下調至 45 美元，而富國銀行則設定了 32 美元的目標價。機構投資者持有該股票的 96.29%</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CAO James George Chopas sold 873 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $19,371.87. Following the completion of the sale, the chief accounting officer directly owned 52,595 shares of the company's stock, valued at approximately $1,167,083.05. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.（納斯達克代碼：APLS - 獲取免費報告）首席會計官 James George Chopas 於 1 月 13 日（星期二）出售了 873 股該股票。股票的平均售價為 22.19 美元，總價值為 19,371.87 美元。出售完成後，首席會計官直接持有公司 52,595 股股票，價值約為 1,167,083.05 美元。這代表其持股比例減少了 1.63%。此次出售在向 SEC 的備案中披露，相關信息可通過 SEC 網站訪問。</p>
</div><h2>Apellis Pharmaceuticals Stock Up 1.0%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票上漲 1.0%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
</div><p>Shares of NASDAQ APLS traded up $0.20 during mid-day trading on Thursday, reaching $20.53. The company had a trading volume of 2,191,474 shares, compared to its average volume of 3,495,767. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of 66.23 and a beta of 0.31. The stock has a fifty day moving average of $22.86 and a two-hundred day moving average of $23.41. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $31.17.</p>
<div class="lb-trans"><p>在週四的午盤交易中，納斯達克 APLS 的股票上漲了 0.20 美元，達到了 20.53 美元。該公司的交易量為 2,191,474 股，而其平均交易量為 3,495,767 股。該公司的債務與股本比率為 0.90，速動比率為 3.10，流動比率為 3.54。公司的市值為 26 億美元，市盈率為 66.23，貝塔值為 0.31。該股票的 50 日移動平均線為 22.86 美元，200 日移動平均線為 23.41 美元。Apellis Pharmaceuticals, Inc.的 12 個月低點為 16.10 美元，12 個月高點為 31.17 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.64. The firm had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company's revenue for the quarter was up 133.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.46) EPS. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（納斯達克代碼：APLS - 獲取免費報告）最近於 10 月 30 日（星期四）發佈了季度財報。公司報告該季度每股收益為 1.67 美元，超出市場共識預期的 1.03 美元，超出幅度為 0.64 美元。該季度的收入為 4.5858 億美元，而分析師預期為 3.6458 億美元。Apellis Pharmaceuticals 的淨利潤率為 4.43%，股本回報率為 18.94%。與去年同期相比，該季度的收入增長了 133.0%。在去年同期，該公司每股收益為（0.46）美元。整體來看，股票研究分析師預計 Apellis Pharmaceuticals, Inc.在當前年度將發佈-1.7 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of APLS. Parallel Advisors LLC grew its position in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after acquiring an additional 855 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock worth $46,000 after purchasing an additional 1,373 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock worth $50,000 after purchasing an additional 857 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock worth $47,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at $64,000. Institutional investors own 96.29% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對 APLS 的持股。Parallel Advisors LLC 在第二季度將其在 Apellis Pharmaceuticals 的持股增加了 80.0%。Parallel Advisors LLC 目前持有該公司 1,924 股股票，價值 33,000 美元，此前在上個季度增持了 855 股。Jones Financial Companies Lllp 在第三季度將其在 Apellis Pharmaceuticals 的持股增加了 206.8%。Jones Financial Companies Lllp 目前持有該公司 2,037 股股票，價值 46,000 美元，此前在上個季度增持了 1,373 股。Allworth Financial LP 在第三季度將其在 Apellis Pharmaceuticals 的持股增加了 64.1%。Allworth Financial LP 目前持有該公司 2,194 股股票，價值 50,000 美元，此前在上個季度增持了 857 股。Osaic Holdings Inc.在第二季度將其在 Apellis Pharmaceuticals 的持股增加了 141.2%。Osaic Holdings Inc.目前持有該公司 2,682 股股票，價值 47,000 美元，此前在上個季度增持了 1,570 股。最後，Quantbot Technologies LP 在第三季度收購了 Apellis Pharmaceuticals 的新股份，價值 64,000 美元。機構投資者持有該公司 96.29% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research analysts have weighed in on APLS shares. Citigroup dropped their target price on Apellis Pharmaceuticals from $52.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, October 31st. Wells Fargo &amp; Company assumed coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They set an &#34;overweight&#34; rating and a $32.00 price objective for the company. Needham &amp; Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Mizuho lowered their price target on Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating on the stock in a research note on Monday, November 3rd. Finally, TD Cowen reduced their price objective on Apellis Pharmaceuticals from $50.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, October 31st. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and an average target price of $33.65.</p>
<div class="lb-trans"><p>幾位研究分析師對 APLS 股票發表了看法。花旗集團在 10 月 31 日（星期五）的研究報告中將 Apellis Pharmaceuticals 的目標價格從 52.00 美元下調至 45.00 美元，並對該股票給予 “買入” 評級。富國銀行在 10 月 15 日（星期三）的研究報告中開始覆蓋 Apellis Pharmaceuticals 的股票。他們給予 “增持” 評級，並設定 32.00 美元的價格目標。Needham &amp; Company LLC 在週二將 Apellis Pharmaceuticals 的目標價格從 29.00 美元下調至 28.00 美元，並對該公司給予 “買入” 評級。瑞穗證券在 11 月 3 日（星期一）的研究報告中將 Apellis Pharmaceuticals 的目標價格從 24.00 美元下調至 19.00 美元，並對該股票給予 “中性” 評級。最後，TD Cowen 在 10 月 31 日（星期五）的研究報告中將 Apellis Pharmaceuticals 的價格目標從 50.00 美元下調至 45.00 美元，並對該公司給予 “買入” 評級。共有 11 位研究分析師對該股票給予 “買入” 評級，7 位給予 “持有” 評級，2 位給予 “賣出” 評級。根據 MarketBeat，Apellis Pharmaceuticals 目前的共識評級為 “持有”，平均目標價格為 33.65 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 APLS 股票分析</strong></p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，以納斯達克代碼 APLS 交易，是一家臨牀階段的生物製藥公司，專注於開發針對補體級聯反應的新療法，以治療罕見且嚴重的疾病。公司的研發工作集中在調節補體蛋白，以應對一系列眼科、血液和腎臟疾病。Apellis 利用其專有的 compstatin 技術平台設計針對性抑制劑，旨在改善患者的治療效果和生活質量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>該公司的主要市場產品 Syfovre（pegcetacoplan）是一種用於治療與年齡相關的黃斑變性引起的地理萎縮的玻璃體內補體 C3 抑制劑，並正在對其他視網膜疾病進行持續研究。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Apellis Pharmaceuticals</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 悄然激活</li>
<li>執行命令 14330：特朗普最大的舉措</li>
<li>崩盤已經開始（大多數人尚未察覺）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Apellis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Apellis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Apellis Pharmaceuticals 並不在名單上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內部人士出售：Apellis Pharmaceuticals（NASDAQ:APLS）的首席會計官出售了價值 19,371.87 美元的股票